Inactive Instrument

Lotus Pharmaceuticals, Inc. Stock Other OTC

LTUS

US5457152032

Valuation: Lotus Pharmaceuticals, Inc.

Market Cap	9.74M 8.52M 7.85M 7.25M 13.77M 929M 14M 93.85M 36.86M 457M 36.55M 35.76M 1.57B	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	14.38M 12.58M 11.6M 10.72M 20.34M 1.37B 20.68M 139M 54.45M 676M 54M 52.83M 2.32B	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

* Estimated data More valuation ratios

Latest news : Lotus Pharmaceuticals, Inc.

23-07-31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
21-11-26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
21-09-28	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
12-05-16	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
12-04-19	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

More news

Press Releases: Lotus Pharmaceuticals, Inc.

12-30	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
25-10-06	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
25-08-12	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
25-02-21	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
24-11-08	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

More press releases

Managers and Directors: Lotus Pharmaceuticals, Inc.

Manager	Title	Age	Since
Georgene Rivers CEO	Chief Executive Officer	-	-

Director	Title	Age	Since
Georgene Rivers BRD	Director/Board Member	-	-

More insiders

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LOTUS PHARMACEUTICALS, INC.	+41.51%	-18.92%	-	-	8.2M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.17%	+1.61%	+16.42%	+85.22%	48.73B
OTSUKA HOLDINGS CO., LTD.	+1.04%	-1.02%	+69.47%	+115.88%	35.82B
CIPLA LIMITED	-0.13%	-1.29%	-2.60%	+41.58%	12.2B
ZYDUS LIFESCIENCES LIMITED	-0.71%	+0.89%	+18.28%	+97.87%	12.11B
KRKA, D. D.	-0.76%	+0.38%	+33.16%	+123.08%	9.11B
ONO PHARMACEUTICAL CO., LTD.	-0.86%	+0.37%	+52.61%	-3.54%	7.09B
GEDEON RICHTER	+0.75%	-0.82%	+17.49%	+44.79%	7B
GLENMARK PHARMACEUTICALS LIMITED	+0.69%	+3.25%	+19.90%	+243.91%	6.7B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+5.45%	-7.36%	-17.93%	+13.17%	5.78B
Average	+4.68%	+0.11%	+22.98%	+84.66%	16.06B
Weighted average by Cap.	+0.33%	+0.39%	+29.79%	+90.75%

	2009	2010
Net sales	57.82M 50.58M 46.65M 43.09M 81.76M 5.51B 83.13M 557M 219M 2.72B 217M 212M 9.34B	72.7M 63.59M 58.65M 54.17M 103M 6.93B 105M 701M 275M 3.42B 273M 267M 11.74B
Net income	16.43M 14.37M 13.26M 12.24M 23.23M 1.57B 23.62M 158M 62.21M 772M 61.7M 60.36M 2.65B	14.42M 12.62M 11.64M 10.75M 20.4M 1.38B 20.74M 139M 54.61M 678M 54.16M 52.98M 2.33B
Net Debt	5.29 4.63 4.27 3.94 7.49 504.9 7.61 51.03 20.04 248.73 19.88 19.44 855.07	4.65 4.06 3.75 3.46 6.57 443.18 6.68 44.79 17.59 218.32 17.45 17.07 750.55

Lotus Pharmaceuticals, Inc. Stock Other OTC

Stocks

LTUS

US5457152032

Pharmaceuticals

Valuation: Lotus Pharmaceuticals, Inc.

Latest news : Lotus Pharmaceuticals, Inc.

Press Releases: Lotus Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Lotus Pharmaceuticals, Inc.

Generic Pharmaceuticals

Financials

Company Profile